Archives

  • 2025-12
  • 2025-11
  • 2025-10

    • BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonis...

    2025-10-25

    BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist for Advanced Neuroscience Research

    Executive Summary: BIIE 0246 is a highly selective antagonist of the neuropeptide Y Y2 receptor (Y2R), with IC50 values of 3.3 nM and Ki values between 8–15 nM under defined assay conditions (ApexBio). It blocks Y2R-mediated presynaptic inhibition, modulates feeding and anxiety behaviors in validated animal models, and is soluble up to 67.2 mg/ml in DMSO. Recent translational work highlights the relevance of NPY/Y2R signaling in the adipose-neural axis, particularly in cardiac arrhythmia (Fan et al., 2024). BIIE 0246 is for research use only and is not indicated for diagnostic or clinical purposes.

    Biological Rationale

    The neuropeptide Y (NPY) system is a key regulator of energy homeostasis, anxiety, and neural circuit activity. NPY exerts its effects via Y1, Y2, Y4, Y5, and Y6 receptors, all G protein-coupled receptors (GPCRs) with distinct expression profiles and physiological roles (Fan et al., 2024). The Y2 receptor (Y2R) is predominantly presynaptic, acting as an auto- and heteroreceptor to inhibit neurotransmitter release. In the central nervous system, Y2R plays a major role in regulating satiety and anxiety behaviors. Peripherally, Y2R modulates gastrointestinal motility and vascular tone. In the context of the adipose-neural axis, increased NPY and Y2R signaling is implicated in metabolic and cardiac pathologies (Fan et al., 2024).

    Mechanism of Action of BIIE 0246

    BIIE 0246 is a non-peptidic, high-affinity antagonist at the neuropeptide Y Y2 receptor. It competitively inhibits the binding of PYY3-36 and NPY to Y2R, with IC50 = 3.3 nM and Ki = 8–15 nM in radioligand assays (ApexBio). By blocking Y2R, BIIE 0246 prevents presynaptic inhibition of neurotransmitter release, thereby enhancing primary afterdischarge activity and excitatory postsynaptic potentials in hippocampal slices. In gastrointestinal tissue, BIIE 0246 fully abrogates PYY3-36-induced contraction. In behavioral models, it reverses Y2R-dependent reductions in food intake and produces anxiolytic-like effects in assays such as the elevated plus-maze. The compound's selectivity profile ensures minimal off-target activity at other NPY receptor subtypes (Peptide-YY.com).

    Evidence & Benchmarks

    • BIIE 0246 demonstrates IC50 = 3.3 nM for Y2R inhibition in PYY3-36 binding assays (ApexBio).
    • Ki values for BIIE 0246 at Y2R range from 8–15 nM, supporting strong target engagement (ApexBio).
    • BIIE 0246 selectively blocks NPY-induced presynaptic inhibition in rat hippocampal slices, restoring neuronal firing (Peptide-YY.com).
    • In vivo, it fully inhibits PYY3-36-induced colonic contraction and attenuates PYY(3-36)-mediated reduction in feeding (Peptide-YY.com).
    • BIIE 0246 exhibits anxiolytic-like effects in the elevated plus-maze behavioral assay (melanocyte-stimulating-hormone-release-inhibiting-factor.com).
    • Recent stem cell-based coculture models implicate NPY/Y1R in arrhythmogenesis, highlighting the need for selective Y2R antagonists to dissect receptor-specific effects (Fan et al., 2024).

    Applications, Limits & Misconceptions

    BIIE 0246 is an established research tool for:

    • Dissecting Y2R-mediated pathways in feeding behavior and satiety studies.
    • Investigating the role of presynaptic inhibition in hippocampal circuitry.
    • Modeling anxiolytic mechanisms in behavioral neuroscience.
    • Exploring the adipose-neural axis and its role in cardiac arrhythmia (Fan et al., 2024).
    • Benchmarking pharmacological selectivity among NPY receptor antagonists (Peptide-YY.com).

    This article extends earlier summaries (Peptide-YY.com) by integrating recent findings on the adipose-neural axis and offering structured experimental recommendations. It also updates mechanistic frameworks discussed in recent translational reviews by focusing on receptor subtype specificity.

    Common Pitfalls or Misconceptions

    • BIIE 0246 is not an agonist—its effect is strictly antagonistic at Y2R.
    • It does not significantly inhibit Y1, Y4, or Y5 receptors at standard concentrations.
    • The compound is not approved for human or veterinary therapeutic use.
    • Long-term storage of working solutions (>1 week) leads to loss of activity.
    • Observed effects in cardiac arrhythmia models require careful receptor subtype attribution (Y2R vs Y1R).

    Workflow Integration & Parameters

    BIIE 0246 is provided as a white solid (C49H57N11O6; MW 896.06 Da). For in vitro studies, dissolve in DMSO (up to 67.2 mg/ml) or ethanol (up to 23.55 mg/ml). Store powder at 4°C. Prepare fresh aliquots prior to each experiment; avoid repeated freeze-thaw cycles. Use concentrations based on published IC50/Ki values, typically in the low nanomolar to micromolar range. For in vivo rodent studies, refer to validated dosing regimens (e.g., 0.5–5 mg/kg, i.p., in behavioral or metabolic assays). The compound is for research use only—not for diagnostic or clinical applications (ApexBio).

    Conclusion & Outlook

    BIIE 0246 remains the reference selective Y2R antagonist for dissecting neuropeptide Y signaling in neuroscience and metabolic research. Its potency, selectivity, and practical formulation parameters streamline experimental design and interpretation. Emerging data on the adipose-neural axis and cardiac arrhythmia underscore the translational value of Y2R antagonism, though careful receptor mapping is essential. For further detail and validated protocols, refer to the product page (BIIE 0246) and recent mechanistic reviews (Unlocking the Translational Power of Y2 Receptor Antagonists).